Biotech · Public company · Wayne, PA, US
Palvella Therapeutics, Inc.
Ticker PVLA · SEC CIK 0001583648
Track this companyFree. Adds Palvella Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials94 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- PTX-022Phase 3 · Pachyonychia CongenitaClinicalTrials.gov · fetched Nov 12, 2026
- QTORIN 3.9% rapamycin anhydrous gelPhase 3 · Pachyonychia CongenitaClinicalTrials.gov · fetched Nov 12, 2026
- QTORIN 3.9% Rapamycin Anhydrous GelPhase 3 · Microcystic Lymphatic MalformationClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 3 · Pachyonychia CongenitaClinicalTrials.gov · fetched Nov 12, 2026
- PTX-022Phase 2 · AngiokeratomasClinicalTrials.gov · fetched Nov 12, 2026
- PTX-022Phase 2 · BCCs in Gorlin Syndrome PatientsClinicalTrials.gov · fetched Nov 12, 2026
- PTX-022Phase 2 · Microcystic Lymphatic MalformationClinicalTrials.gov · fetched Nov 12, 2026
- QTORIN 3.9% rapamycin anhydrous gelPhase 2 · Cutaneous Venous MalformationsClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle comparatorPhase 2 · BCCs in Gorlin Syndrome PatientsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)PHASE2 · RECRUITING · started Apr 1, 2026ClinicalTrials.gov NCT07552077 · fetched Nov 12, 2026
- A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 20, 2024ClinicalTrials.gov NCT06653842 · fetched Nov 12, 2026
- SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 31, 2024ClinicalTrials.gov NCT06239480 · fetched Nov 12, 2026
- A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia CongenitaPHASE3 · RECRUITING · started Nov 15, 2022ClinicalTrials.gov NCT05643872 · fetched Nov 12, 2026
- Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic MalformationsPHASE2 · COMPLETED · started Jan 13, 2022ClinicalTrials.gov NCT05050149 · fetched Nov 12, 2026
- A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia CongenitaPHASE3 · COMPLETED · started Nov 29, 2021ClinicalTrials.gov NCT05180708 · fetched Nov 12, 2026
- CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin SyndromePHASE2 · COMPLETED · started May 6, 2021ClinicalTrials.gov NCT04893486 · fetched Nov 12, 2026
- VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia CongenitaPHASE3 · COMPLETED · started Sep 1, 2020ClinicalTrials.gov NCT04520750 · fetched Nov 12, 2026
- Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia CongenitaPHASE2_PHASE3 · COMPLETED · started Apr 1, 2019ClinicalTrials.gov NCT03920228 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
NIH awards3
- SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic MalformationsFiscal year 2026 · $484.5KNIH RePORTER 5R01FD008196-03 · fetched Nov 12, 2026
- SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic MalformationsFiscal year 2025 · $648.8KNIH RePORTER 5R01FD008196-02 · fetched Nov 12, 2026
- SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic MalformationsFiscal year 2024 · $479.6KNIH RePORTER 1R01FD008196-01A1 · fetched Nov 12, 2026